Publication at First Faculty of Medicine |
2019
Abstract
Metastatic castration-resistant prostate cancer is a severe disease. Recently, however, its therapy has been significantly enriched adding novel treatment options extending patient overal survival.
Enzalutamide targets multiple steps in the androgen-receptor signaling pathway. In patients with metastatic castration-resistant prostate cancer, enzalutamid has become a cornerstone of the treatment due to results of AFFIRM and PREVAIL studies.
The overview article describes the current position of enzalutamid in the treatment of this malignancy.